Identification of Inhibitors Based on Molecular Docking: Thyroid Hormone Transmembrane Transporter MCT8 as a Target

Area of Science:

• Biochemistry
• Pharmacology
• Computational Chemistry

Background:

• Monocarboxylate Transporter 8 (MCT8) is crucial for thyroid hormone transport in the liver and brain.
• Mutations in MCT8 cause Allan-Herndon-Dudley Syndrome (AHDS), a debilitating neurological disorder with no current treatment.
• Discovering novel MCT8 inhibitors is essential for developing effective AHDS therapies.

Purpose of the Study:

• To identify natural compounds that can inhibit the activity of MCT8.
• To explore the potential of natural products in drug discovery for AHDS.

Main Methods:

• Molecular docking simulations were employed to screen 24 natural kinase inhibitors against the MCT8 protein.
• Binding affinities were assessed using Autodock Vina, with drug-likeness evaluated via Swiss ADME and Lipinski's rule of five.
• Binding energies were compared against positive controls like triac, desipramine, and silychristin.

Main Results:

• Emodin demonstrated the highest binding energy (-8.6 kcal/mol), followed by helenaquinol, cercosporamide, and resveratrol.
• Emodin and helenaquinol exhibited superior binding affinities compared to positive controls.
• Cercosporamide and resveratrol showed competitive binding energies relative to established controls.

Conclusions:

• The identified natural compounds, particularly emodin and helenaquinol, are promising candidates for further investigation.
• These compounds may offer a potential therapeutic strategy for the prevention and treatment of AHDS.
• Further preclinical and clinical evaluations are warranted to confirm the efficacy and safety of these natural inhibitors.